

## Myanmar

### Support for Vaccine: Pneumococcal conjugate vaccine (PCV)

#### This Decision Letter sets out the Programme Terms of a Programme

This Decision Letter forms part of the Partnership Framework Agreement and together with the Partnership Framework Agreement sets out the Programme Terms of the Programme. Any term used in this Decision Letter but not defined shall have the meaning given to such term in the Partnership Framework Agreement. The English language version of this Decision Letter shall prevail in the case of any conflict with terms expressed in any other language.

1. **Country:** Myanmar

2. **Vaccine grant number:** MMR-PCV-R

3. **Date of Decision Letter<sup>1</sup>:** 03 October 2022

4. **Date of the Partnership Framework Agreement (the "PFA"):** 04 April 2014

5. **Programme title:** New Vaccine Support (NVS), Pneumococcal conjugate vaccine (PCV), Routine

6. **Requested product presentation and formulation of vaccine:**

7. **Programme duration<sup>2</sup>:** 2016-2022

8. **Annual Amounts:** (subject to the terms of the PFA)

This is the total amount approved by Gavi for the entire duration of the programme. Annual amounts are defined as per section 4.1 of the PFA. The annual amounts are indicative and not limited for use for the specified year. Any requested adjustments to the Annual Amounts will be subject to Gavi approval. It is essential that Country's Health Sector Coordination Committee (or its equivalent) be involved with this process both in its technical process function and its support during implementation and monitoring of the Programme. Further, amounts are indicative and are subject to the availability of funds and relevant approvals by the Gavi Board.

	2016-2022	2023	2024	2025	2026	2027	Total
Annual Amounts (US\$)	70.975.989	-	-	-	-	-	70.975.989

9. **Vaccine introduction grant:**

<sup>1</sup> This Decision Letter will apply for the programme duration. Gavi will only update this Decision Letter in the event of the following: i) release of future year approvals; ii) adjustments to initial quantities; iii) product price changes or product switches; and/or iv) co-financing amounts.

<sup>2</sup> This is the entire duration of the programme.

Approval		
Year	Grant number	Amount (US\$)
2016	MMR-PCV-R-VIG-UNIC	607.638
2016	MMR-PCV-R-VIG-WHO	443.866

**10. Product switch grant:**

Not applicable

**11. Indicative annual amounts:** (subject to the terms of the PFA)

Gavi Support	2016 - 2022	2023		2024		2025		2026		2027	
Material		Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)	Units	Total Cost (US\$)
<b>Total amounts (US\$)</b>	<b>70.975.989</b>		-		-		-		-		-

**12. Procurement agency:**

Not applicable

**13. Self-procurement:**

Self-procurement applies. Please refer to the Partnership Framework Agreement terms and conditions.

**14. Co-financing obligations (indicative)<sup>3</sup>:**

Not applicable

**15. Operational support for campaigns:**

Not applicable

**16. Additional Reporting Requirements:**

<sup>3</sup> Gavi may adjust the outlined co-financing obligations based on the corresponding actual dose shipments to the country. Any over/under co-financed doses/amounts will be settled in subsequent payments.

Reports and other information :	Due dates
To enable the annual release of purchase orders, Country shall report closing stock levels by 31 <sup>st</sup> March of each calendar year. <sup>4</sup>	31 March
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

---

**17. Financial clarifications:**

Not applicable

---

**18. Other conditions:**

Not applicable

For Gavi  
Signed by



Colette Selman  
**Director, Core Countries**  
03 October 2022

---

<sup>4</sup> Reporting requirements are subject to change. Countries may be required to submit quarterly or monthly stock reports. Country will be notified of updated reporting requirements separately.